✦ LIBER ✦

Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma : Phase II trials of the Minnie Pearl Cancer Research Network

✍ Scribed by John D. Hainsworth; Howard A. Burris III; Frederic T. Billings III; James E. Bradof; Margaret Baker; F. Anthony Greco

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 94 KB
Volume: 92
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20011101)92:9<2391::aid-cncr1587>3.0.co;2-m

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly docetaxel in the treatment of eld

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma : A Minnie Pearl Cancer Research Network Phase II Trial

✍ John D. Hainsworth; Howard A. Burris III; Sharlene Litchy; Lisa H. Morrissey; Jo 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Background: Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. in the current phase ii trial, the authors evaluated the feasibility, toxicity, and efficacy of weekly docetaxel in the treatme

Gemcitabine and vinorelbine in the secon

Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients : A Minnie Pearl Cancer Research Network Phase II trial

✍ John D. Hainsworth; Howard A. Burris III; Sharlene Litchy; Joan B. Erland; Jerem 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

## BACKGROUND. Second-line chemotherapy for patients with nonsmall cell lung carcinoma has been ineffective due to the lack of activity of older agents following platinum-based therapy. This Phase II trial evaluated the feasibility, toxicity, and efficacy of two active new agents, gemcitabine and v

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati